Skip to main content

Table 1 Baseline characteristics of the aspirin and non-aspirin therapy groups

From: Association between aspirin therapy and the outcome in critically ill patients: a nested cohort study

Variable Aspirin
N = 154
Non-aspirin
N = 609
Crude
P value
PS adjusted
P-Value
Age (yrs) mean ± SD 65 ± 16.5 48.8 ± 21.7 <0.0001 0.88
Gender, n (%)     
 Female 56 (36.4) 152 (25) 0.005 0.97
 Male 98 (63.6) 457 (75.1)   
Diabetes, n (%) 102 (66.2) 201 (33.8) 0.0001 0.22
Admission category, n (%)     
 Non-operative 145 (94.2) 495 (81.3) 0.0001 0.21
 Post-operative 9 (5.8) 114 (18.7)   
APACHE II, mean ± SD 26.5 ± 7.2 22.9 ± 8.2 <0.0001 0.67
Mechanical ventilation, n (%) 135 (87.7) 548 (90) 0.40 0.93
SOFA on day 1, mean ± SD 9.3 ± 3.3 9.2 ± 3.5 0.82 0.52
Sepsis, n (%) 47 (30.5) 147 (24.1) 0.104 0.68
Chronic respiratory disease, n (%) 43 (27.9) 114 (18.7) 0.011 0.19
Chronic cardiac disease n (%) 76 (49.4) 81 (13.3) <0.0001 0.86
Chronic liver disease n (%) 9 (5.8) 45 (7.4) 0.50 0.54
Chronic immunosuppression n (%) 11 (7.1) 55 (9.1) 0.45 0.30
Chronic renal disease n% 38 (24.7) 65 (10.7) 0.0001 0.43
GCS, mean ± SD 9.0 ± 4.2 8.6 ± 4.1 0.23 0.70
Vasopressor, n (%) 106 (68.8) 390 (64.1) 0.26 0.36
PaO2/FiO2 ratio, mean ± SD 200 ± 98 221 ± 119 0.04 0.88
Statin use n% 74 (48.1) 33 (5.4) <0.0001 0.83
Bilirubin (μmol/L), mean ± SDa 31.2 ± 69.4 36.1 ± 70 0.50 0.26
Creatinine (μmol/L), mean ± SDa 199.9 ± 171.2 148.8 ± 146.5 0.0002 0.15
INR, mean ± SD 1.5 ± 0.8 1.5 ± 0.9 0.73 0.26
Platelet, x 109/L mean ± SD 193.1 ± 121 247.9 ± 133.3 <0.0001 0.048
  1. P-values are provided for the differences between the two groups significant before and after propensity score adjustment
  2. APACHE Acute physiology and chronic health evaluation, GCS Glasgow coma scale, INR International normalized ratio, PS propensity score, SOFA Sequential Organ Failure Assessment
  3. aTo convert to conventional units in mg/dL, divide by 88.4 for creatinine and 17.1 for bilirubin